The Clinical Trials Network of Tennessee (CTN2) at the University of Tennessee Health Science Center has contracted a new clinical trial to test possible therapeutics for COVID-19 in hospitalized patients. This new trial brings the total generated by CTN2 contracts for the university to nearly $7 million.
E-Mail
Memphis, Tenn. (May 11, 2021) - The Clinical Trials Network of Tennessee (CTN2) at the University of Tennessee Health Science Center has contracted a new clinical trial to test possible therapeutics for COVID-19 in hospitalized patients. This new trial brings the total generated by CTN2 contracts for the university to nearly $7 million.
Since its launch in 2018, CTN2 has brought more than 200 clinical trial opportunities to the university and the citizens of Tennessee. Steven R. Goodman, PhD, vice chancellor for Research at UTHSC, who led the creation of CTN2, lauded the tremendous success of the nonprofit that enables clinical research faculty across all the UTHSC campuses, who are affiliated with hospitals, to effectively respond to opportunities for clinical trials with pharmaceutical, biotech, and medical device industry partners.
Effective supply chain surveillance for PPE thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
The Society of Asian American Scientists in Cancer Research April 11 announced that it has honored 10 Indian American scientists for their outstanding cancer research.
Dr. Rajvir Dahiya, professor emeritus at U.C. San Franciscoâs School of Medicine and president of SAASCR, presented awards to these scientists April 11 during the American Association for Cancer Research annual meeting, according to the news release.
The awardees were Drs. Zaver M. Bhujwalla, Pankaj K. Singh, Neil Bhowmick, Anand Srivastava, Neeraj Saxena, Kaustubh Datta, Bhagavatula Moorthy, Nagi Kumar, Parameswaran Hari and Arun Sreekumar.
Bhujwalla is the William R. Brody Professor in the Russell H. Morgan Department of Radiology and Radiological Science of the Johns Hopkins University School of Medicine.
Study: Stereotactic body radiotherapy can be safely used to treat patients with multiple metastases
The first National Institutes of Health (NIH) National Cancer Institute (NCI)-funded clinical study examining stereotactic body radiotherapy (SBRT) in the treatment of oligometastatic breast, prostate, and non-small cell lung (NSCLC) cancers displayed evidence that SBRT can be safely used to treat patients who have multiple metastases. These results were recently published in
JAMA Oncology.
The results of the Phase I NRG-BR001 trial, conducted by the NCI National Clinical Trials Network group NRG Oncology, indicate that SBRT treatment in standard doses was safe for 35 evaluable patients with a median of 3 metastases. There were no dose-limiting toxicities and over 50% of trial participants were alive at 2 years following treatment.